Form 4: Avidity Biosciences' CSTO, W. Michael Flanagan, Executes Option and Sells Shares Under 10b5-1 Plan

W. Michael Flanagan, CSTO of Avidity Biosciences, exercised stock options and sold 62,500 shares of common stock on October 1, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On October 1, 2024, W. Michael Flanagan, the Chief Scientific and Technology Officer (CSTO) of Avidity Biosciences, Inc., exercised stock options to acquire 62,500 shares of common stock at a price of $26.75 per share.
• Simultaneously, Flanagan sold 62,500 shares of common stock at a weighted-average price of $47.6178, with individual sales ranging from $47.00 to $48.20.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on June 12, 2024.
• Following these transactions, Flanagan directly owns 85,389 shares of Avidity Biosciences common stock and options to purchase 25,000 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions executed under a pre-arranged trading plan. There is no indication of positive or negative implications for the company.

Industry Context

Form 4 filings are a routine part of the US stock market and are required by the SEC to ensure transparency when company insiders trade their own company's stock. The use of a 10b5-1 trading plan is a common practice to avoid accusations of insider trading, as it allows insiders to pre-schedule trades at a time when they are not in possession of material non-public information.

Key Dates